Golimumab for the treatment of psoriatic arthritis.

Health technology assessment (Winchester, England)

Volumn 15 Suppl 1, Issue , 2011, Pages 87-95

  Yang, H ^a   Epstein, D ^b   Bojke, L ^b   Craig, D ^b   Light, K ^b   Bruce, I ^b   Sculpher, M ^b   Woolacott, N ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; GOLIMUMAB; MONOCLONAL ANTIBODY;

COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; PALLIATIVE CARE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886943092     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta15suppl1/10     Document Type: Review

References (0)